Core Wealth Partners LLC Acquires 413 Shares of Pfizer Inc. (NYSE:PFE)

Core Wealth Partners LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 2.7% in the 1st quarter, HoldingsChannel.com reports. The fund owned 15,747 shares of the biopharmaceutical company’s stock after purchasing an additional 413 shares during the quarter. Core Wealth Partners LLC’s holdings in Pfizer were worth $437,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in PFE. GoalVest Advisory LLC boosted its holdings in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth $32,000. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the period. VisionPoint Advisory Group LLC boosted its holdings in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the 4th quarter worth $36,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PFE. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, June 26th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Price Performance

Shares of PFE stock traded down $0.13 during mid-day trading on Thursday, reaching $27.70. The company’s stock had a trading volume of 15,180,087 shares, compared to its average volume of 29,961,926. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80. The company has a market cap of $156.96 billion, a P/E ratio of -461.59, a PEG ratio of 1.09 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm’s 50-day moving average is $27.99 and its two-hundred day moving average is $27.71.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter last year, the company posted $1.23 EPS. On average, research analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.06%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.